Literature DB >> 16271098

Long-term transfusion of polymerized bovine hemoglobin in a Jehovah's Witness following chemotherapy for myeloid leukemia: a case report.

Yash P Agrawal1, Matthew Freedman, Zbigniew M Szczepiorkowski.   

Abstract

A 52-year-old female Jehovah's Witness presented with relapsed secondary acute myeloid leukemia. Because of chemotherapy-induced anemia, she was infused with the bovine hemoglobin (Hb)-based oxygen carrier HBOC-201 (Biopure) as the sole means of transfusion support. HBOC-201 has only been used for management of acute hemorrhage, and its utility in providing longer term transfusion support is unknown. Over a period of 18 days, a total dose of 1230 g of HBOC-201 was delivered. Although the patient succumbed to the disease after 18 days of treatment, this case documents our experience with the highest dose and duration of HBOC-201 ever used. Although possible renal toxicity could not be definitively excluded, the homogeneous extraction of oxygen by the brain in the presence of and perhaps from HBOC-201 was demonstrated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16271098     DOI: 10.1111/j.1537-2995.2005.00599.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  2 in total

1.  A Jehovah's Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions.

Authors:  Yumi Yamamoto; Akihito Kawashima; Eri Kashiwagi; Kiyoyuki Ogata
Journal:  Case Rep Hematol       Date:  2014-10-02

Review 2.  New Applications of HBOC-201: A 25-Year Review of the Literature.

Authors:  Min Cao; Yong Zhao; Hongli He; Ruiming Yue; Lingai Pan; Huan Hu; Yingjie Ren; Qin Qin; Xueliang Yi; Tao Yin; Lina Ma; Dingding Zhang; Xiaobo Huang
Journal:  Front Med (Lausanne)       Date:  2021-12-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.